Oral remibrutinib hits Phase 3 primary endpoint for inducible hives
1. Oral remibrutinib successfully met its primary endpoint in the Phase III RemIND trial, delivering significant symptom relief for chronic ...
Tag: BTK inhibitor
Rilzabrutinib demonstrates rapid and durable clinical activity for immune thrombocytopenia
1. Rilzabrutinib was active and 400mg twice daily was identified as the dose for further testing with low-level toxic effects. ...
#VisualAbstract: Pirtobrutinib is safe and efficacious in the treatment of relapsed or refractory B-cell malignancies (BRUIN Trial)
1. Bruton’s tyrosine kinase inhibitor pirtobrutinib showed efficacy in the treatment of relapsed or refractory B-cell malignancies such as chronic ...
